DIRS.INFO The most relevant business & tech news

☆ People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication
▼ + stars: | 2023-03-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Patients taking blockbuster obesity drugs Ozempic or Wegovy will pack the pounds back on after they stop taking the medications. Studies have similarly shown weight rebound in people who stop taking Ozempic. So has Ozempic, which was first authorized to treat diabetes and is now being used off-label for weight loss. The shortage and other factors like out-of-pocket costs without insurance or unpleasant side effects have forced some people to stop taking Ozempic or Wegovy. Conde-Knape said so far data indicate that weight loss is maintained with long-term use of the drugs.

☆ As markets turn rocky, these global stocks look resilient and are expected to rally
▼ + stars: | 2023-03-15 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Stocks slid, with the Dow Jones Industrial Average posting its fifth straight day of declines on Monday, while the 2-year Treasury yield tumbled . The screen threw up a mix of health care, consumer, utility and even some financial stocks. Canadian financial services firm Fairfax Financial Holdings and Japanese natural gas provider Tokyo Gas got among the highest expected earnings growth for this year – at more than 150% each. British bank HSBC also made it to the list, with nearly 50% expected earnings growth and 23% average upside. Italian luxury sports car maker Ferrari made the screen, with 21% expected earnings growth and around 20% upside.

☆ Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln
▼ + stars: | 2023-02-15 | by ( ) www.reuters.com time to read: +1 min

Feb 15 (Reuters) - Danish pharmaceuticals company Bavarian Nordic (BAVA.CO) has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc (EBS.N) for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023. The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. Bavarian Nordics makes the only approved mpox vaccine and started receiving massive orders last year as the virus became a global issue. The company expects 2023 revenue of about 6 billion Danish crowns ($863 million) against the 3.15 billion crowns in preliminary 2022 results, with 4.4 billion crowns coming from mpox and smallpox vaccined contracts alone. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to reach 2.2 billion crowns this year, up from 329 million crowns in the preliminary results for 2022.

☆ Market veteran says a new bull market is 'not far away' — and reveals how to play it
▼ + stars: | 2022-11-08 | by ( Zavier Ong | ) www.cnbc.com time to read: +2 min

The stock market has experienced a series of bear market rallies this year. Demmert said the bear market is now its "third and final phase." It is now in its 11 th month of a typical 12–15-month cycle, according to Demmert — indicating that a bottom could be close. "It's sort of an all-weather company at this point because they have the dominant exposure in that market globally. "That's where people go where they think it's safe, such as Google [parent Alphabet ] and Microsoft in the tech space.

Search resuls for: "Danish pharma"

4 mentions found